Search

Your search keyword '"Reinhard, Christoph"' showing total 14 results

Search Constraints

Start Over You searched for: Author "Reinhard, Christoph" Remove constraint Author: "Reinhard, Christoph" Publication Type Conference Materials Remove constraint Publication Type: Conference Materials
14 results on '"Reinhard, Christoph"'

Search Results

2. Abstract 1761: Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in models of human high-grade serous ovarian cancer (HGSOC)

3. Abstract 3513: The CHK1 kinase inhibitor prexasertib (LY2606368) shows potent single-agent efficacy inin vitroandin vivomodels of castrate-resistant prostate cancer

4. Abstract 3508: Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) models

5. Abstract 3513: The CHK1 kinase inhibitor prexasertib (LY2606368) shows potent single-agent efficacy inin vitroandin vivomodels of castrate-resistant prostate cancer

6. Abstract LB-083: Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity inKRASmutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)

7. Abstract LB-083: Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity inKRASmutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)

8. Abstract 336: Anti-tumor activity of the Chk1 inhibitor prexasertib (LY2606368) as a single agent in triple negative breast cancer models

9. Abstract 317: Combination of a novel ERK1/2 inhibitor (LY3214996) with CDK4 and CDK6 inhibitor (abemaciclib) enhances antitumor efficacy in KRAS mutant non-small cell lung cancer (NSCLC)

10. Abstract 4104: Intrinsic and acquired resistance to cetuximab in colorectal cancer patients

11. Abstract 849: Molecular characterization of primary tumor & the paired liver metastatic biopsies of colorectal cancer reveals a critical role of immunosuppression, EMT & angiogenesis in cancer metastasis

12. Abstract 2818: An unbiased tumor cell panel profiling method to identify drug-drug interactions reveals synergy between the CDK4 and CDK 6 inhibitor abemaciclib and the Raf dimer and pan-Raf inhibitor LY3009120 in Ras mutant cancers

13. Abstract 2829: Preclinical analysis and characterization of abemaciclib using three-dimensional patient-derived colorectal cancer organoid cultures

14. Abstract 2978: Generation of drug response data from 57 new patient-derived colon cancer xenografts and 3D cell cultures for systematic correlation with tumor biology within the OncoTrack* project

Catalog

Books, media, physical & digital resources